What sitagliptin “transaminase US patent application” results are you likely seeing on Google Patents?
People searching for “sitagliptin transaminase US patent application” on Google Patents are usually looking for US patent publications that mention:
- sitagliptin (or sitagliptin-containing compositions)
- transaminase (often ALT/AST) or liver enzyme monitoring
- treatment of a condition linked to elevated liver enzymes or drug-induced liver injury risk
Google Patents is a search engine over patent documents, so the exact application number/publication can change depending on whether you search for:
- “sitagliptin transaminase”
- “sitagliptin ALT”
- “sitagliptin AST”
- “liver transaminase” or “elevated transaminase”
- combinations like “sitagliptin + transaminase” with filters (US publications only)
If you paste the exact Google Patents URL or the text you’re seeing (title, assignee, or publication number), I can help interpret what that specific US application covers.
How to find the right US application faster on Google Patents
Use targeted Google Patents queries so you don’t pull unrelated “transaminase” mentions:
- Query: sitagliptin transaminase
- Narrow to US: add country:US (or use the US filter in Google Patents)
- If you want liver enzymes specifically: try sitagliptin ALT or sitagliptin AST
- If you care about claims/uses: add keywords like method or treating plus elevated or increased
Then look at the publication type and date:
- US publication numbers look like US20xx... (published application) or sometimes US... granted patents.
- The application may be published before the final patent issues.
What these patent documents typically claim (when they mention transaminase)
When sitagliptin and transaminase are both present in a patent, claims commonly relate to one of these themes:
- a method of treatment that includes monitoring liver enzymes (ALT/AST/transaminase) during therapy
- identification of patients at risk for elevated transaminases and adjusting therapy
- compositions or treatment regimens that address hepatobiliary safety signals
- related biomarkers or diagnostic approaches tied to liver enzyme changes
Patent wording matters here: “monitoring” can be in the description, while “method claims” may explicitly require transaminase evaluation.
If you meant “transaminase” in the context of safety—what to check
For patient-facing relevance, check whether the US application is about:
- adverse event management or risk mitigation (e.g., stopping/holding treatment when transaminases rise)
- diagnostic thresholds (how high ALT/AST must be)
- specific patient populations (pre-existing liver disease, alcohol use, etc.)
Those details determine whether it’s a true “transaminase/safety” patent versus a broader scientific mention.
Need the exact Google Patents sitagliptin transaminase US application number?
Reply with either:
1) the Google Patents link you’re looking at, or
2) the title + assignee, or
3) any visible publication number (for example, starting with “US20”)
and I’ll pinpoint the US application/publication and summarize what it claims around transaminase.